Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Probutate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 4/20 | 0.82 |
| ▸ | AR | P10275 | 3/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.82 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Probutate SCHEMBL30507561 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL4778 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL4280673 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| Hydrocortisone Probutate SCHEMBL14339602 | 1.00 | PGR (0.82) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL122187 | 0.97 | PGR (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL4290159 | 0.97 | PGR (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL605474 | 0.97 | NR3C2 (0.85) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL4278627 | 0.95 | PGR (0.91) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10858602 | 0.94 | PGR (0.81) | PGRARCHRM1NR3C2NR3C1 | |
| SCHEMBL10535271 | 0.94 | NR3C2 (0.80) | PGRARCHRM1NR3C2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660029-B1 | USE OF PENTYLENE GLYCOL AS SOLVENT FOR HYDROCORTISONE OR DERIVATIVES THEREOF | ORÉAL L (FR) | 2015-03-18 | — | — | EP | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-4902682-A | W/O cream containing hydrocortisone diester | BEIERSDORF AG (DE) | 1990-02-20 | — | — | US | claimed |
| JP-54128560-A | — | — | None | — | — | JP | disclosed |
| US-12202831-B2 | Small molecule inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-21 | — | — | US | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-11787807-B2 | Small molecule inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-17 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| EP-4086256-A1 | SMALL MOLECULE INHIBITORS OF THE JAK FAMILY OF KINASES | Janssen Pharmaceutica NV (BE) | 2022-11-09 | — | — | EP | disclosed |
| EP-3555097-B1 | IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE COMPOUNDS AS INHIBITORS OF JANUS KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-15 | — | — | EP | disclosed |
| US-20210340143-A1 | Small Molecule Inhibitors of the JAK Family of Kinases | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | US | disclosed |
| US-5322685-A | Containing diglycerol fatty acid ester, plyvalent metal salt of fatty acid, acid salt, oil, water, active ingredient | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1994-06-21 | — | — | US | disclosed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | disclosed |
| US-5190936-A | Nonionic lipids vesicles | L'OREAL (FR) | 1993-03-02 | — | — | US | disclosed |
| EP-0484529-A1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-5023251-A | Storage stability; skin disorders | BEIERSDORF AG (DE) | 1991-06-11 | — | — | US | disclosed |
| US-4902682-A | W/O cream containing hydrocortisone diester | BEIERSDORF AG (DE) | 1990-02-20 | — | — | US | disclosed |
| US-4290962-A | HYDROCORTISONE 17-BUTYRATE-21-PROPIONATE, USEFUL AS AN ANTIINFLAMMATORY AGENT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1981-09-22 | — | — | US | disclosed |
| US-4290962-A | HYDROCORTISONE 17-BUTYRATE-21-PROPIONATE, USEFUL AS AN ANTIINFLAMMATORY AGENT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1981-09-22 | — | — | US | disclosed |
| JP-S54128560-A | HYDROCORTISONE DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1979-10-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787807-B2 | Small molecule inhibitors of the JAK family of kinases | JAK2, JAK1, JAK3 | NR3C1 2388/4885PGR 1671/4885AR 4107/4885 |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | NR3C1 2868/4885PGR 1789/4885AR 4669/4885 |
| US-20210340143-A1 | Small Molecule Inhibitors of the JAK Family of Kinases | JAK1, JAK2, JAK3 | NR3C1 2624/4885PGR 2318/4885AR 4639/4885 |
| US-12202831-B2 | Small molecule inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | NR3C1 2624/4885PGR 2318/4885AR 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.